SB-267268 is a selective and nonpeptidicalpha(v)beta3 (αvβ3)andalpha(v)beta5 (αvβ5)integrins antagonist, withK_is of 0.9, 0.5 and 0.7 nM for humanαvβ3, monkeyαvβ3and humanαvβ5, respectively. SB-267268 inhibits human and mouseαvβ3withIC₅₀s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis andVEGFexpression^[1].

SB-267268 was much less potent for inhibition of human, mouse, and ratαvβ6 integrin. SB-267268 inhibits the attachment of bothαvβ3-transfected HEK293 cells to microtiter plate wells precoated with arginine-glycine-aspartic acid (RGD)-containing matrix proteins with IC₅₀values of 12 nM. SB-267268 also inhibits vitronectin-mediated human and rat aortic smooth-muscle-cell (SMC) migration with IC₅₀values of approximately 12.3 nM and 3.6 nM, respectively^[1].

SB-267268 (60 mg/kg; bi-daily, i.p.) reduces blood vessel profiles (BVPs) in the inner retina by 50%^[1].
In ROP mice treated with SB-267268, VEGF and VEGFR-2 gene expression in the inner nuclear layer (INL) and the ganglion cell layer (GCL) is reduced^[1].

451.44

C₂₂H₂₄F₃N₃O₄

205678-26-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.